"Pharmaceutical Speed Reading Society" central media bitterly approved surrogacy abandonment and another drug company Alzheimer's disease research...

January 19, 2021 / Medical Information At a Glance: Central media painfully approved surrogacy abandonment phenomenon; another pharmaceutical company Alzheimer's disease research failed; Fuhong Hanjun Adamo single anti-new adaptation was approved ... Daily fresh medicine news, speed reading society and you pay attention to! Part1 policy brief Heilongjiang added 27 new cases of confirmed 43 new cases asymptomatic January 18 0-24, Heilongjiang Province added 27 new confirmed cases of coronary pneumonia (2 cases of Yanhua Anda City, Yihua City, Beilin District asymptomatic infected persons into confirmed cases 1 case, Qiqihar City Angxi District asymptomatic infected persons into confirmed cases 1 case, Wangkui County, Wangkui County, 23 cases of asymptomatic infection.
43 new cases of asymptomatic infection (20 cases in Wangkui County, 6 cases in Huanhua City, 2 cases in Yuhua City, 2 cases in Yanhua Anda City, 1 case in Angxi District of Qiqihar City, 1 case in Limin Development Zone in Harbin City, and 11 cases in Hulan District of Harbin City).
(CCTV News) Jilin new local confirmed cases 43 cases, including 9 cases in Changchun City Tonghua City 34 cases on January 18 0-24, the province added 43 new local confirmed cases (9 cases in Changchun City, 34 cases in Tonghua City), of which 36 cases from the previously reported asymptomatic infected people into confirmed cases.
Up to now, the province has reported a cumulative total of 83 confirmed cases (25 cases in Changchun City, 58 cases in Tonghua City), of which 3 cases of critical heavy duty, 11 cases of heavy duty, 61 cases of ordinary type, 8 cases of light.
as of 24 hours on January 18, the province had reported a total of 221 locally confirmed cases, a total of 136 cases of cured discharge, 83 cases of isolation in hospital and 2 cases of death.
(Jilin Weijian Committee) Hebi City, Henan Province, 2 cases of asymptomatic infection: once on the K262 train January 18, 2021, Hebi City, the new crown pneumonia epidemic prevention and control command office informed: January 17, Hebi City, Henan Province found 2 cases of overseas import asymptomatic infection, with 16 reported asymptomatic infected people on a certain flight from Israel.
two infected people had taken the K262 train (15 cars 31, 13 cars 33) on January 14, the terminal is Beijing West Station.
from Zhengzhou Station to Hebi Station, the journey time is about two hours.
(Medical Geography) Hebei added 5 new cases of local diagnosis January 19, Hebei outbreak prevention and control release notice: 19 0:00 to 10:00, Hebei added 5 new locally confirmed cases, all in Shijiazhuang City, Weicheng District;
(Caixin) village doctor reported not timely sentenced according to Jingmen Evening News reported that a village doctor in Jingmen, Hubei Province, because of the discovery of fever patients did not report in time, resulting in a number of villagers were later diagnosed.
recently, the Shayang County People's Court in Jingmen City, Hubei Province, handed down a verdict in the case, and Ma was sentenced to one year's imprisonment, suspended for two years, for obstructing the prevention and control of infectious diseases.
(Primary Physicians Commune) 2021 CDE Release: Circulars 1 and 2 of 2021 CDE on January 15, 2021 and January 18, 2021, respectively, No. 1 of 2021 and No. 2 of 2021 The specific content is to further guide the development of innovative drugs for the treatment of post-menopaphic osteoporosis by publishing the "Technical Guidelines for Imaging Evaluation Procedures for Anti-Tumor Drug Clinical Trials" circular, developing clinical trial imaging evaluation procedures, regulating industry operations, clarifying technical standards, and publishing the "Technical Guidelines for Clinical Trials of Innovative Drugs for the Treatment of Post-Menopaoper osteoporosis".
(dandelion) central media bitterly criticized the phenomenon of surrogacy abandonment recently, because a star surrogacy to abandon the incident exposure of surrogacy black illegal industrial chain once again to the public eye, CCTV news on the afternoon of the 19th also in the media platform for this matter, and criticized surrogacy abandonment is a legal and moral difficult thing.
Part2 production and observation of another listed company divestiture of hospital assets exit from the medical industry on January 18, listed company Changbao shares issued a notice that, in accordance with the company's strategic development needs, in order to further effectively integrate resources, optimize the asset structure, continue to promote the implementation of the previous plan to withdraw from the medical services industry related matters, the implementation of the main energy pipe industry focus.
company will sell its 100% stake in Shandong Ruigao, 100% stake in Shishan Second Hospital and 90% stake in Yuyanghe People's Hospital to Zhongmin Jiaye and Shanghai Jiayu Medical.
January 17, the company has signed a "hospital equity purchase agreement" with Zhongmin Jiaye and Jiahe Medical.
(Medical) Thyme Bio announced the granting of an exclusive license to Etana Dayo in Indonesia On 19 January, Thyda Bio announced a cooperation agreement with Etana, an Indonesian biotechnology company, in which Thyda Bio granted Etana Dayo an exclusive license in Indonesia, and Etana is committed to bringing Etana Tong to the local market.
will receive development and sales milestone payments and a double-digit percentage of net sales.
specific financial terms are not suitable for disclosure.
( Agency ) Part3 drug news another drug company Alzheimer's disease research failure recently , Biohaven pharmaticals announced that its third generation is expected to regulate the body's excitable neurotransmitter glutamate in the study of the drug troriluzole test failed to have an impact on the devastating progression of AD .
In the focused analysis of completed troriluzole as the primary and critical secondary data of phase 2/3 clinical trials for the treatment of mild and moderate AD symptoms, troriluzole showed no statistical improvement at 48 weeks compared to the placebo group, using the Alzheimer's Assessment Scale Cognitive Subscale 11 and the Clinical Dementia Assessment Scale.
primary secondary endpoint, the sea mass was assessed by magnetic resonance imaging through magnetic resonance imaging throughout the population, and troriluzole was no different from the placebo group.
(Sina Pharmaceutical News) First-line treatment of pancreatic cancer Innovative CD73 inhibitor combination therapy reached 41% objective mitigation rate, Arcus Biosciences announced that its target CD73 small molecule inhibitor AB680, in the treatment of metastatic pancreatic cancer in early clinical trials to obtain positive preliminary data.
with chemotherapy and anti-PD-1 antibodies, the objective remission rate of first-line treatment of pancreatic cancer reached 41%, which was better than the historical performance of standard therapy.
as a small molecule inhibitor, AB680 may have better tumor permeability and greater inhibition than anti-CD73 antibodies.
(Pharmaceutical) PD-L1 and CD16 dual-specific NK cell therapy PD-L1 t-haNK showed strong results recently, NantKwest and another immunotherapy company ImmunityBio jointly announced the early interim results of the PD-L1 t-haNK trial.
data show that in patients with advanced metastatic pancreatic cancer who do not have other FDA-approved treatment options, the medium survival rate of PD-L1 t-haNK combination therapy is twice the historical survival rate.
these trials, based on the initial cancer moon landing and the exploratory QULT trial launched in 2017, seem to validate a theory that by coordinating NK and T cell therapies, survival rates can be improved without the need for large doses of chemotherapy.
(Bio Valley) Lilly Alzheimer's Drug Phase 2 Clinical Positive Data Recently, Lilly published the interim results of a Phase 2 clinical trial of Alzheimer's disease in the new drug donanemab, which showed that donanemab monoantigen removal of β amyloid plaques in the brain helped Alzheimer's patients significantly slow cognitive and daily functional decline.
specifically, the medium-term results reached the primary endpoint of the Change in the Alzheimer's Comprehensive Score Scale from baseline to 76 weeks, with a 32 percent decrease in the overall score in the mono-antitherapy group compared to placebo.
(Medical Valley) Boan bio-new crown and antibody completion phase I. clinical all subjects into the group of green leaf pharmaceutical company Boan bio-independent research and development of innovative antibody products for the treatment of new coronary pneumonia - LY-CovMab has completed phase I clinical trials in China all subjects into the group.
preclinical efficacy studies of LY-CovMab showed that LY-CovMab was effective in treating and preventing SARS-CoV-2 infections.
LY-CovMab is a highly potency medium antibody that responds effectively to viral mutations.
addition, LY-CovMab can effectively avoid ADE effects.
the FDA approved Johnson and Johnson Darzalex Faspro's treatment for light-chain amyloid degeneration, the FDA approved Johnson and Johnson's Xi'an Jansen's Darzalex Faspro for the treatment of newly diagnosed adult patients with light-chain amyloid degeneration.
notable, Darzalex Faspro is also the first and only FDA-approved treatment for people with this allergy.
this time, the FDA approved the drug in a joint use with boronicazome, cyclophosphamide and dexamison.
Darzalex Faspro was originally developed by Genmab and in May last year the drug was approved for four treatments for multiple myeloma, including for newly diagnosed multiple myeloma patients, multiple myeloma patients who are not eligible for transplantation, and patients with recurring or resusable multiple myeloma.
(Xinhua) -- The U.S. FDA has granted fast-track eligibility to Padeliporfin ImPACT, Steba Biotech announced recently, and the FDA has granted fast-track eligibility for the treatment of adult patients with low-level and single-urethra-based urethra cancer.
this follows a new research drug application approved in December 2020 that allows the start of a critical Phase 3 clinical trial of Padeliporfin ImPACT in low-level UTUC patients, which is expected to begin in the first quarter of 2021.
(Bio Valley) SGL1/2 inhibitor Zynquista received positive regulatory feedback from the FDA Lexicon Pharmaceuticals recently announced that it has received regulatory feedback from the FDA, and the results of its Phase 3 clinical studies SOLOIST and SCORED can support SGLT 1/2 inhibitor-type sotagliflozin new drug application: for adult patients with type 2 diabetes with worsening heart failure or additional risk factors for heart failure, reducing the risk of cardiovascular death, hospitalization for heart failure, and emergency care.
(Bio Valley) Singapore Tesha Bio-Innovative Therapy is eligible for EMA Priority Drug: Treatment of Lymphoma Tesha Bio recently announced that EMA has granted its CD30 directed self-embedded antigen-infused antigen-treated T-cell therapy priority drug eligibility for the treatment of recurring or refractic classic Hodgkin's lymphoma.
last year, the FDA awarded this self-called CD30 CAR-T cell therapy for R/R cHL advanced regenerative medicine.
(Bio Valley) Boya series because CRISPR / Cas 9 gene editing therapy was approved clinical January 18, Boya because of the announcement that the National Drug Administration Drug Review Center has approved its blood transfusion dependence β thalassemia CRISPR / Cas9 gene editing therapy product ET-01 clinical trial application, this is the first national drug regulatory agency approved to carry out clinical trials of gene editing therapy products and hematopoietic stem cell products.
ET-01 clinical trial is a multi-center, open,single-arm clinical study that will evaluate the safety and effectiveness of ET-01 single transplants in patients with blood transfusion-dependent β thalt-thalassemia.
(Pharmaceutical Rubik's Cube Info) Huluwa: obtained the Changchun Xitin injection drug registration certificate January 19, Huluwa Pharmaceutical Industry announced that recently received the NMPA approved the issuance of the Changchun Sedin injection "drug registration certificate."
this listing application was accepted by the Hainan Provincial Drug Administration in January 2015.
, the company has invested a total of RMB 356.46 million (unaudited) in research and development.
is intended to be used to improve the brain infarction sequelae, cerebral hemorrhage sequelae, cerebral arteriosclerosis and other induced symptoms.
(Huluwa Pharmaceutical Announcement) Anhui Hongye Pharmaceuticals le cartilage tablets were approved on January 18, NMPA official website shows that Anhui Hongye Pharmaceuticals according to the imitation of the 4 categories of reported production of hydrochloric acid lecades flat tablets were approved and treated as the same, becoming the third domestic.
is a commonly used antihypolytic drug, and in 2019 sales of Lecadesping, a public medical institution in China and a physical pharmacy terminal in Chinese cities, were close to 300 million yuan, according to Mienet data.
the drug is suitable for the treatment of mild and moderate primary hypertension.
(Hongye Pharmaceuticals Announcement) Fuhong Hanjun Adamu single anti-new anti-new adaptive disease was approved on January 18, Fosun Pharma issued an announcement, its development of Adamo single anti-injection new staphylacticitis adaptation by the NMPA drug registration supplementary application for review and acceptance.
Adamu monoantigen anti-monoclonal antibody biosynthic drug developed independently for Fuhong Hanxuan, in December 2020 has been approved in China (excluding Hong Kong, Macao and Taiwan region) listed, approved for listing of the adaptive diseases for psoriasis, rheumatoid arthritis, strong straight spina bifida.
this time to the State Drug Administration to apply for the relevant supplementary, mainly for the new drug to add staphylococcitis adaptation.
(Pharmaceutical Geography) Nvolly single anti-injection application was included in the NMPA priority review on January 19, Corning Jerry announced that the recombinant humanized PD-L1 monolithic antibody Nvoli single-anti-injection application was included in the NMPA drug review center for priority review, the first application for the adaptation of the previous standard treatment failure of microsatellite unstable advanced colorectal cancer, stomach cancer / mismatch repair function of other defective entities.
(AAP) Coenbet ibuprofen particles through generic drug consistency evaluation January 19, Conebe Pharmaceuticals announced that recently received the State Drug Administration issued on ibuprofen particles "drug supplemental application approval", the drug through generic drug consistency evaluation.
ibuprofen particles, as a commonly used anti-heat analgesic, have been included in the National Health Insurance Directory (2020 edition), is a category B medical insurance drugs, of which 0.1g specifications in the OTC specification can be explicitly used for children aged 1-3 years.
mainly for slowing down